Abstract
Acute liver allograft rejection is a serious complication after liver transplantation. Interferon regulatory factor 4 (IRF4) is expressed predominantly in the immune system and plays an important role in its development and function. However, the role of IRF4 in liver transplantation has never been investigated. In our current study, to evaluate the effect of IRF4 inhibition on recipient survival, IRF4 siRNA, or control siRNA, or PBS was injected into the liver allograft recipients through caudal vein. The survival time of mice treated with IRF4 siRNA (MST=31.5days) was prolonged significantly compared with that of mice treated with PBS (MST=6days) or control siRNA (MST=6.5days) (P<0.001). IRF4 siRNA treatment displays lower induction of pro-inflammatory levels, including TNF-α, IL-6 and IFN-γ, and higher induction of anti-inflammatory IL-10 levels. Administration of anti-IL-10 into IRF4 siRNA-treated mice resulted in shortened allograft survival and increased rejection scores. Furthermore, IRF4 inhibition promotes M2 macrophage differentiation invivo and invitro. And inhibition of macrophages with GdCl3 reverses the prolonged liver allograft survival and decreased liver rejection scores induced by IRF4 siRNA. In conclusion, inhibition of IRF4 attenuates acute liver allograft rejection in mice, and this is associated with promoted M2 macrophage differentiation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
